Sandoz, a key player generic and biosimilar medicines, on Tuesday announces the launch of Hyrimoz (adalimumab) citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively across European markets, starting today.
Hyrimoz HCF, like the currently available 50mg/mL version of Hyrimoz, is indicated for all conditions covered by the reference medicine: rheumatic diseases, Crohn’s disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa.
“People living with chronic inflammatory conditions can experience debilitating effects on daily life. The launch of Hyrimoz HCF in Europe is a key milestone in offering an additional treatment option to those that need it and showcases our unwavering commitment to expanding access to high-quality medicines,” Rebecca Guntern, President Europe Sandoz said.
According to the company’s statement, the launch of Hyrimoz HCF strengthens the Sandoz biosimilar portfolio in immunology, including Erelzi (biosimilar etanercept), Zessly (biosimilar infliximab) and Rixathon (biosimilar rituximab, including rheumatoid arthritis indication). Hyrimoz citrate-free HCF (adalimumab-adaz) launched in the US in July 2023, it added.
Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably across a range of areas including immunology, oncology, supportive care, and endocrinology, it stated.
It has a global portfolio with eight marketed biosimilars and a further 25 assets in various stages of development. Since launching the first biosimilar in Europe in 2006, Sandoz has helped to create early and expanded patient access to life-altering medicines while increasing healthcare savings and creating competition that fuels further innovation.
